Powder: | Yes |
---|---|
Customized: | Customized |
Certification: | GMP, ISO 9001, USP, BP |
Suitable for: | Adult |
State: | Solid |
Purity: | >99% |
Samples: |
---|
Customization: |
---|
Suppliers with verified business licenses
Product name:Cabazitaxel Powder |
Other Name: Cabazitaxel; XRP-6258;TXD 258;7β,10β-Dimethoxydocetaxel |
Appearance:White Powder |
CAS:183133-96-2 |
M.F:C45H57NO14 |
M.W.:835.93 |
Specification:99% |
Cabazitaxel (previously XRP-6258) is a semi-synthetic derivative of a natural taxoid. It was developed by Sanofi-Aventis and was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.
Cabazitaxel in combination is a treatment option for hormone-refractory prostate cancer following docetaxel-based treatment.
Cabazitaxel anticancer mechanism and characteristics similar with docetaxel, belongs to anti-microtubule drugs. Cabazitaxel through binding to tubulin, promoting their assembly into microtubules, and can prevent these have assembled a microtubule disintegration of the stabilization of microtubules, thereby inhibiting cell mitosis, and interphase cellular functions (interphasecellularfunctions) of play.
Related Product
Product Name | CAS No. | Product Name | CAS No. |
Lufenuron | 103055-07-8 | Toltrazuril | 69004-03-1 |
Nitenpyram | 120738-89-8 | Praziquantel/Biltricide | 55268-74-1 |
Fenbendazole | 43210-67-9 | Tetramisole Hcl | 5086-74-8 |
Levamisole | 14769-73-4 | Ponazuril | 9004-4-2 |
Diclazuril | 101831-37-2 | Florfenicol | 73231-34-2 |
Ivermectin | 70288-86-7 | Enrofloxacin Hcl | 112732-17-9 |
Albendazole | 54965-21-8 | Mebendazole | 31431-39-7 |
ITEM | SPECIFICATION | RESULT | METHOD |
Appearance | White powder, neutral odor, highly hygroscopic | Conforms | Visual |
Identification | Standard solution and test solution same spot,RF | Conforms | TLC |
Specific Optical | -2.4°~ -2.8° | -2.72° | |
Heavy metals (as PB) | ≤10ppm | Conforms | AAS |
Sulfate (SO4) | ≤0.02% | Conforms | Colorimetry |
Chloride (Cl) | ≤0.02% | Conforms | Colorimetry |
Phosphate Ion (P) | ≤5ppm | Conforms | Colorimetry |
Residual solvent(ethanol) | ≤1.0% | Conforms | HS-GC |
pH | 4.5~7.0 | 5.10 | |
Related substance | Spot not bigger than standard solution spot | No spot | TLC |
Water Content | ≤2% | 0.26% | KF |
Assay (dried basis) | 98.0%--102.0% | 99.48% | Potentiometric titration |
Assay (dried basis) | 98.5%--100% | 99.2% | HPLC |
Function:
Cabazitaxel's anti-cancer mechanism and characteristics are similar to docetaxel and belong to anti-microtubule drugs. Cabazitaxel promotes its assembly into microtubules by binding to tubulin, while preventing the disassembly of these assembled microtubules, stabilizing microtubules, thereby inhibiting cell mitosis, and interphase cellular functions.
Suppliers with verified business licenses